China's medical products administrator approved Hutchmed's (HKG:0013) supplemental new drug application for its savolitinib drug for a type of locally advanced or metastatic non-small cell lung cancer, according to a Tuesday filing with the Hong Kong Exchange.
The drug, branded Orpathys, is indicated for non-small cell lung cancer with MET exon 14 skipping alteration mutation, which is seen in patients over 70 years old.
China also converted the conditional approval for Orpathys into a full one, the filing said.
Shares closed 3% higher in Hong Kong during Tuesday's trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。